On Friday, President Trump issued three executive orders (and threatened a fourth) outlining sweeping changes he planned to make regarding prescription drug prices in the United States. One order seeks to make federal grants to federally qualified health centers contingent upon discounted insulin prices. A second would allow personal and wholesale importation of prescription drugs from overseas. The third implements rebate reform for pharmacy benefits managers (PBMs).

If we have learned one thing since January 20, 2017, it is that congressional Democrats will tie themselves into knots to oppose President Trump. We’ve also learned that the President’s opponents bristle at his self-proclaimed “America First” agenda. These trends have once again reared their ugly heads when it comes to the United States-Mexico-Canada Agreement (USMCA).

In his first State of the Union speech, President Trump once again promised to lower the swelling costs of prescription drugs. The question is – will the administration do it without imposing price controls.

Deficit spending by the federal government is growing almost as fast as the waistline of average Americans according to recent data. While it is no secret that obesity rates in the country have been on the rise, new information reveals the obesity epidemic is reaching unprecedented proportions. Nearly two-thirds of adults and one-third of children are considered overweight or obese, and that number is projected to rise dramatically in the near future.

The growth of America’s government may soon be outpaced by growth of the average waistline new indicators reveal. Rates of obesity have been increasing over the past several decades, but are now reaching some incredible levels. Currently it's estimated that well over one-third of adults are classified as obese and nearly two-thirds are classified as overweight. Perhaps more distressing is the recent discovery that one in six children are suffering from obesity.